Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPL389 in moderate to severe atopic dermatitis (ZEST Trial)
NCT03517566Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of adriforant in atopic dermatitis (AD) (5 arms), sponsored by Novartis. Primary endpoint: Percentage of IGA Responders at Week 16. Started Nov 2018; status: terminated.
02
Drugs
adriforant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03517566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517566.